Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes
Sequel Med Tech to Integrate twiist Automated Insulin Delivery (AID) System with Abbott’s Future Dual Glucose-Ketone SensorIntegration of Abbott’s glucose-ketone sensor with the twiist™ AID System aims to enhance early identification of rising ketones to detect the risk of diabetic ketoacidosis (DKA)1
Sequel Announces First CGM Integration for its twiist AID System: Abbott's FreeStyle Libre 3 Plus Sensortwiist™ AID system powered by Tidepool expected to launch Q2 2025 in the U.S. with Abbott’s FreeStyle Libre® 3 Plus sensor
Sequel’s twiist™ Automated Insulin Delivery System Receives FDA 510(k) ClearanceDevice Bundles Latest Technology to Deliver Significant Advancements for Insulin Management for People with Type 1 Diabetes
